New drug shows promise for tough kidney diseases

NCT ID NCT05732402

Ongoing Disease control Sponsor: Alpine Immune Sciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called povetacicept in adults with certain autoimmune kidney diseases, including lupus nephritis and IgA nephropathy. The goal is to see if the drug is safe and can help control the disease. Participants receive the drug every 4 weeks for at least 6 months, with possible extensions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anti-neutrophil cytoplasmic antibody-associated vasculitis eosinophilic granulomatosis with polyangiitis granulomatosis with polyangiitis idiopathic membranous glomerulonephritis IgA glomerulonephritis lupus nephritis membranous glomerulonephritis microscopic polyangiitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS IMMUNOGLOBULIN A NEPHROPATHY LUPUS NEPHRITIS MEMBRANOUS NEPHROPATHY

Contacts and locations

Locations

Investigational Site (102)

Nedlands, Western Australia, 6009, Australia
Investigational Site (116)

Suwon, Gyeonggi-do, 16499, South Korea
Investigational Site (118)

Colleyville, Texas, 76034, United States
Investigational Site (125)

Seoul, Gyeonggi-do, 03080, South Korea
Investigational Site (191)

Caguas, 00725, Puerto Rico
Investigational Site (501)

Phoenix, Arizona, 85302, United States
Investigational Site (502)

Lawrenceville, Georgia, 30046, United States
Investigational Site (503)

Boston, Massachusetts, 02115, United States
Investigational Site (504)

Goyang-si, Gyeonggi-do, 10444, South Korea
Investigational Site (505)

Anyang-si, Gyeonggi-do, 14068, South Korea
Investigational Site (506)

Valencia, California, 91335, United States
Investigational Site (507)

Cheonan, Chungcheongnam-do, 31151, South Korea
Investigational Site (508)

Brooklyn, New York, 11203, United States
Investigational Site (509)

Newark, New Jersey, 07103, United States
Investigational Site (510)

Guri-si, Gyeonggi-do, 11923, South Korea
Investigational Site (511)

Albany, New York, 12209, United States
Investigational Site (512)

Orlando, Florida, 32806, United States
Investigational Site (513)

Arvada, Colorado, 80002, United States
Investigational Site (515)

Saint Albans, Victoria, 3021, Australia
Investigational Site (516)

Houston, Texas, 77054, United States
Investigational Site (518)

Bethlehem, Pennsylvania, 18017, United States
Investigational Site (519)

Concord, New South Wales, 2139, Australia
Investigational Site (520)

Seoul, Gyeonggi-do, 03181, South Korea
Investigational Site (521)

Seoul, Gyeonggi-do, 05278, South Korea
Investigational Site (523)

Phoenix, Arizona, 85016, United States
Investigational Site (524)

Tucson, Arizona, 85712, United States
Investigational Site (525)

Tamarac, Florida, 33321, United States
Investigational Site (526)

Irving, Texas, 75061, United States
The Johns Hopkins University School of Medicine

Baltimore, Maryland, 21224, United States
Washington University School of Medicine in St. Louis

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.